Team. Thanks for joining us dan. We're gonna talk about immunotherapy compuserve and its efforts to pursue novel targets for ahmed cancer types. Perhaps we can been gin with the idea of checkpoint inhibitors what are they. And how do they work. He'd be taurus. Are actually proteins modulating the immune system responds in the context of fay affair. Kasim yuna therapy. It was identified. There is a crosstalk between immune cells and and the cancer. This crosstalk is being done through immune checkpoint and and usually these are inhibiting the immune system response to the to the cancer to the cancer cells and and the drugs the few drugs that are out there that are dressing these same immune checkpoint skin to treat cancer. Patients are actually am inhibiting. The inhibition exerted by immune checkpoint on the cancer cells in diff- therefore allowing the immune system to be stimulated and actually fight the cancer. This has been a a real revolution in cancer. Care but these still have limited efficacy. How how effective are these therapies at treating cancer today as of today about twenty to thirty percent of the patient population of the cancer patients are responsive to these drugs. It is increasing with time. We're more proven are being done with the current in hebrew tours. But i have to say that you know. Cancer is a movie factoria disease and and it's actually a collection of many different diseases and we're not in a situation where one treatment fits all basically declined immune checkpoint a drugs are addressing only few number drug targets and they're still many mechanisms that need to be a still a explored and and identified and drugs need to be developed in order to address the various mechanisms of action by which the kansas are actually avoiding the immune system. And here's actually that were. Competent fits in and see what we do. Discover new drug targets and developer first in class drugs to address. These struck targets copy. Jen has developed a computational based drug discovery platform. What is the platform. And how does it work. So the platform is is basically based on twenty years a fan and know how that was built at computation with being a computational discovery company for many years and then after we established a critical mass of discovery capabilities. We turn to be to. We are today. Pretty discovery and development company in generale with built computer systems tucson algorithms in order to be able to address the challenge of new drug targets discovery. And you biological halfway discovery. Identify new drug targets is a is a is a very complex isn't f. fourteens. Multiday mentioned effort and for that we had to develop a multiple systems. We've built a lot of know-how in the company and we've built a Expertise in what is called multi onyx analysis. We're not limiting our platform to a specific data type or a specific technology. Actually we're very flexible. Tools and systems an algorithms are really designed to address multiple data sources multiple data technologies and. This is because this is multifactorial and complex and filled to work in. An all of these are augmented with human expertise that we have in the company in the last twenty years. How do the targets. You've discovered differ from the targets that today's checkpoint inhibitors go after and it's very good question. Actually it's not very different in terms of you know still it's checkpoint but i think that the nature of checkpoints one as compared to the others those that are known and those that we discovered these are proteins. That are very different from one. Another so yes all of them. At least those are defined as negative customer tour costing military checkpoints. They're all inhibiting the immune system response against the cancer. But they're doing it in different ways and what we discovered is as i said you know the checkpoints are now have been translated to drugs that are in the market. A really only very few. I think about three or sociology for pd one. Pedia want and what we discovered. Is you know you biological pathways debts allowed us to discover new immune. Checkpoint that are still inhibiting the immune system response against the cancer but in a different way a different mechanism and this allows us to be able to develop hopefully no new treatments solutions. That will address those cancer patients the not responsive to the current checkpoint inhibitors check on earth. What are the issues with. Existing immunotherapy is the ability of cancers to develop resistance. Where are you doing to address that issue so this is actually exactly what we're trying to do. Am that in cancer. Immunotherapy is there are two issues right there. Ease the patients that are not responsive in does that with time that are developing what is called acquired resistance. We're we're trying to do in. The company is to try and focus on those biological pathways that we believe would address those patients that are not responsive to the current checkpoint blockade. So they're in different ways with different. Mechanism does cancers data and actually deliver a different solution to the problem. And this will were trying to work on. You know the leading the leading drug that is in development at is now owning phase one studies and we have owning michel data in the clinic but the days actually am supporting designs behind. We discovered so we discovered a completely new biological pathway identified sen typically that it is addressing am in. You am a new mechanism that still this family of immune checkpoint. The preclinical data suggested that it should address